• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of immunotherapy >Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients
【24h】

Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients

机译：NSCLC患者血浆PD-1和PD-L1表达水平及临床意义研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

As new members of the CD28/B7 costimulatory superfamily, PD-1 (programmed cell death 1) and its ligand PD-L1 (programmed cell death ligand 1) mediate a negative costimulatory signal, which inhibits functioning and proliferation of T and B cells, and reduce interleukin-2, interleukin-10, and interferon-γ secretion. This inhibitory pathway plays an important role in immune escape and the microenvironment of the tumor, and closely related to tumor progression. sPD-1 and sPD-L1 are the soluble form of PD-1 and PD-L1 in peripheral blood, which had not been well investigated. In this study, sPD-1 and sPD-L1 level in peripheral blood of non–small cell lung cancer (NSCLC) patients were determined, and their correlation to clinicopathologic features and long-term survival of these patients were analyzed, so as to provide references for further investigations. Plasma sPD-1 and sPD-L1 levels in 88 NSCLC patients and 40 healthy controls were determined by enzyme-linked immunosorbent assay, and their correlation to clinicopathologic features and long-term survival of these patients were analyzed. Our study showed that the plasma sPD-1 and sPD-L1 were higher in NSCLC patients than in healthy controls, and plasma sPD-L1 and sPD-L1/sPD-1 ratio independently and positively correlated with overall survival of NSCLC patients. This study provides a reference for the assessment of prognosis and risk stratification for NSCLC patients, as well as for immune treatment of cancer.
机译：作为CD28 / B7的新成员，PD-1（编程细胞死亡1）及其配体PD-L1（编程的细胞死亡配体1）介导负性共鸣信号，其抑制T和B细胞的功能和增殖，并减少白细胞介素-2，白细胞介素-10和干扰素-γ分泌。该抑制途径在免疫逃逸和肿瘤的微环境中起重要作用，与肿瘤进展密切相关。 SPD-1和SPD-L1是外周血中的PD-1和PD-L1的可溶形式，其尚未得到很好的研究。在本研究中，确定了非小细胞肺癌（NSCLC）患者外周血的SPD-1和SPD-L1水平，并分析了与这些患者的临床病理特征和长期存活的相关性，以提供参考进一步调查。通过酶联免疫吸附试验确定了88例NSCLC患者和40例健康对照中的血浆SPD-1和SPD-L1水平，分析了与这些患者的临床病理特征和长期存活的相关性。我们的研究表明，NSCLC患者的血浆SPD-1和SPD-L1高于健康对照，血浆SPD-L1和SPD-L1 / SPD-1的比例独立，与NSCLC患者的整体存活相比。本研究为NSCLC患者的预后和风险分层提供了评估，以及免疫治疗癌症的参考。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号